NCT00542685

A 10-Week Study Evaluating the Efficacy And Safety of PD 0332334 for the Treatment of Generalized Anxiety Disorder

A Phase 3, Randomized, Double-Blind, Placebo Controlled, Parallel Group, 10-Week Study Evaluating the Efficacy And Safety of PD 0332334 for the Treatment of Generalized Anxiety Disorder

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 551 (actual)
• Sponsor: Pfizer · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

This study will evaluate the efficacy and safety of PD 0332334 for the treatment of generalized anxiety disorder.

Conditions

• Generalized Anxiety Disorder

Interventions

Type	Name	Description
DRUG	PD 0332334	Capsules, oral, 300 mg BID, 8 weeks with 2 week taper.
DRUG	Placebo	Capsules, oral, placebo BID, 8 weeks with 2 week taper.
DRUG	PD 0332334	Capsules, oral, 225 mg BID, 8 weeks with 2 week taper.
DRUG	PD 0332334	Capsules, oral, 175 mg BID, 8 weeks with 2 week taper.

Timeline

• Start date: 2007-10-01
• Primary completion: 2008-12-01
• Completion: 2008-12-01
• First posted: 2007-10-11
• Last updated: 2012-11-16

Locations

43 sites across 1 country: United States